Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal

Journal of Medical Economics

Volumn 18, Issue 8, 2015, Pages 565-572

  Laires, Pedro A ^a   Ejzykowicz, Flavia ^a   Hsu, Tun Ying ^a   Ambegaonkar, Baishali ^a   Davies, Glenn ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Cardiovascular disease; Coronary heart disease; Cost effectiveness; Ezetimibe; Rosuvastatin; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADD ON THERAPY; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; MEDICAL HISTORY; PORTUGAL; PORTUGUESE (CITIZEN); PREVALENCE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMBINATION DRUG THERAPY; CORONARY DISEASE; COST BENEFIT ANALYSIS; DOSE RESPONSE; DYSLIPIDEMIAS; ECONOMICS; MIDDLE AGED; RISK FACTOR; SMOKING;

AGED; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EZETIMIBE; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PORTUGAL; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; ROSUVASTATIN CALCIUM; SMOKING;

EID: 84964389177     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1031794     Document Type: Article

References (29)

1. American Heart Association. Heart Disease and Stroke Statistics-2003. Update. Dallas, TX: American Heart Association, 2003
2. Instituto Nacional de Estatistica, Statistics Portugal. portuguese Life Table 2007-2009. http://www.ine.pt/. Accessed October 1, 2013
3. Soini EJ, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26:25-36
4. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;13;376:1670-81
5. Reckless J, Davies G, Tunceli K, et al. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health 2010;13:726-34
6. da Silva PM, Cardoso SM. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol 2011;30:47-63
7. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55
8. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (Mercury I) study. Am Heart Journal 2004;147:705-12
9. Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-hdl cholesterol and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (Mercury II). Am Heart J 2006;151:975.e1
10. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78.17
11. Bullano MF, Kamat S, Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 2007;64:276-84
12. Fox KM, Gandhi SK, Ohsfeldt RL, et al. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 2007;13(10 Suppl):S270-5
13. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
14. Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Chicago, IL: American Heart Association Scientific Sessions, 2014
15. Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004;22(3 Suppl):37-48
16. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadminis-tration in statin-treated patients not at cholesterol goal. Application to Germany, Spain and Norway. Pharmacoeconomics 2004;22(3 Suppl):49-61
17. van Nooten F1, Davies GM, Jukema JW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J 2011;19:61-7
18. National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143
19. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
20. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J 2000;139:272-81
21. Goodacre S, Nicholl J, Dixon S, et al. Randomized controlled trial and economic evaluation of a chest pain observation unit compared with routine care. Br Med J 2004;7434:254-7
22. McCormack T, Harvey P, Gaunt R, et al. IN-PRACTICE study Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010;64:1052-61
23. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 2003;145:36-41
24. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. http://www.nice.org.uk/TA094. Accessed August 13, 2013
25. Infarmed, Prontuário Terapêutico On-Line. 2015. http://www.infarmed.pt/prontuario/index.php. Accessed February 1, 2015
26. Ministério da Saúde, Diåio da Republica -I Série, no 21 (Portaria no 20/2014) de 29 de Janeiro de 2014
27. Pereira R, Gouveia M, Martins AP. Análise custo-efectividade de sitaglipina quando adicionada a metformina em doentes com diabetes tipo 2 em Portugal. Revista Portuguesa de Diabetes 2012;7:13-23
28. Ara R, Pandor A, Tumur I, et al. Estimating health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Therapeut 2008;30:1508-23
29. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92